Development of a novel class of CBP/EP300 bromodomain inhibitors which block TNF-α induced NFκB signaling
Authors:
- Katherine GosseléKGKatherine Gosselé
- Irene LatinoILIrene Latino
- Eleen LaulELEleen Laul
- Mariia KirillovaMKMariia Kirillova
- Vlad PascanuVPVlad Pascanu
- Emanuele CarloniECEmanuele Carloni
- Rajiv BediRBRajiv Bedi
- Amedeo CaflischACAmedeo Caflisch
- Santiago GonzalezSGSantiago Gonzalez
- Cristina NevadoCNCristina Nevado
Preprint
- 26 March 2024
- preprint
- Published by American Chemical Society (ACS) in ChemRxiv
Abstract
Tumor Necrosis Factor α (TNF-α) is an inflammatory cytokine that is a key mediator in autoimmune disorders such as Crohn’s disease and rheumatoid arthritis (RA). Targeting epigenetic regulators of cytokine transcription and signaling is a promising therapeutic approach. However, the specific mechanisms by which they contribute to the immune response are not well established yet. Here, we present a new class of selective CBP/EP300-bromodomain (BRD) inhibitors comprising a 3-methylcinnoline as acetyl-lysine mimic discovered by high-throughput docking of a fragment library. These compounds inhibit NFκB signaling in THP-1 cells, reducing TNF-α-induced cytokine expression in vitro. Furthermore, when tested in vivo, BRD inhibitors reduced the pro-inflammatory response by decreasing the secretion of IL-1β, MCP-1, IL-1α, and IL-6 from TNF-α-stimulated animals and inhibiting the migration of innate immune cells towards the draining lymph node. The results of this study confirmed CBP/EP300-BRD as valid therapeutic targets for autoimmune diseases and our inhibitors represent a promising new class of non-cytotoxic therapeutic agents for treating RA.Keywords
All Related Versions
This publication has 59 references indexed in Scilit:
- Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancerBioorganic & Medicinal Chemistry, 2021
- Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C‐C Motif Chemokine Ligand 2–Mediated Angiocrine SignalingHepatology, 2021
- Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 AcetylationCell Reports, 2019
- Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 AcetylationCell Reports, 2018
- Macrophage Death following Influenza Vaccination Initiates the Inflammatory Response that Promotes Dendritic Cell Function in the Draining Lymph NodeCell Reports, 2017
- The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylasesBiochemical Pharmacology, 2016
- Binding Mode of Acetylated Histones to Bromodomains: Variations on a Common MotifChemMedChem, 2015
- Inhibiting NF-κB activation by small molecules as a therapeutic strategyBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2010
- Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule InhibitorChemistry & Biology, 2010
- TNF? and the TNF receptor superfamily: Structure-function relationship(s)Microscopy Research and Technique, 2000